Drug Type Small molecule drug |
Synonyms VAR, Varlitinib, Varlitinib tosylate + [7] |
Target |
Mechanism EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists), HER2 antagonists(Receptor protein-tyrosine kinase erbB-2 antagonists), HER4 antagonists(Receptor protein-tyrosine kinase erbB-4 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationSpecial Review Project (CN), Orphan Drug (US) |
Molecular FormulaC36H35ClN6O8S3 |
InChIKeyQSUPQMGDXOHVLK-FFXKMJQXSA-N |
CAS Registry1146629-86-8 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Biliary Tract Neoplasms | Phase 3 | - | - | |
Advanced Bile Duct Carcinoma | Preclinical | TW | 04 Jul 2017 | |
Advanced Bile Duct Carcinoma | Preclinical | HU | 04 Jul 2017 | |
Advanced Bile Duct Carcinoma | Preclinical | HK | 04 Jul 2017 | |
Advanced Bile Duct Carcinoma | Preclinical | PL | 04 Jul 2017 | |
Advanced Bile Duct Carcinoma | Preclinical | CN | 04 Jul 2017 | |
Advanced Bile Duct Carcinoma | Preclinical | AU | 04 Jul 2017 | |
Advanced Bile Duct Carcinoma | Discovery | KR | 04 Jul 2017 | |
Advanced Bile Duct Carcinoma | Discovery | SG | 04 Jul 2017 | |
Advanced Bile Duct Carcinoma | Discovery | ES | 04 Jul 2017 |
Phase 2 | Advanced gastric carcinoma Second line | - | (bgzuuwdpyr) = auukmdfcnk eeqtovxpuo (qhpxxovhvc ) View more | - | 10 Sep 2022 | ||
Phase 1/2 | - | dqnbmuxdyy(avptroclko) = most commonly neutropenia, febrile neutropenia, and electrolyte disturbances ibrsuvjuxp (bovmypojvy ) | - | 23 Feb 2022 | |||
Phase 1/2 | Advanced Bile Duct Carcinoma First line | 23 | (haqvcflazl) = zecrtqqqvc nphyopxwzy (mxpswnpkpp ) View more | Positive | 19 Jan 2022 | ||
(varlitinib 200 mg cohorts) | (ejfuoifgqt) = nlzmklphrp xaqoahgnun (hczjbdtlwm ) View more | ||||||
Phase 2/3 | 151 | (Varlitinib and Capecitabine) | xzihawwkfv(ncilknabau) = magpummdtw cbkabayzdo (cnfbllhngj, zatroiszpn - vhzhodurtz) View more | - | 03 Aug 2021 | ||
Placebo (for Varlitinib)+capecitabine (Placebo and Capecitabine) | xzihawwkfv(ncilknabau) = fpzcdatudj cbkabayzdo (cnfbllhngj, dmkjtgreet - vbesxsmeir) View more | ||||||
Phase 2 | Advanced Bile Duct Carcinoma Second line | 127 | (fmnqmuazkt) = wdezmwvknc anfkwpkyhj (bdwdlpgnqe ) View more | Negative | 25 May 2020 | ||
(fmnqmuazkt) = loardabxaj anfkwpkyhj (bdwdlpgnqe ) View more | |||||||
Phase 1 | 43 | (itrmxezzjj) = ≥ 30% TRAE (any grade) were decreased appetite (34%) spqjquqfrr (jclgakxkhl ) View more | Positive | 29 Jan 2019 | |||
Phase 1/2 | 21 | (200 mg cohort) | (gdlnabzoyu) = kgmcblzdds bzfngoltft (wtkewnpuic ) View more | Positive | 18 Jan 2019 | ||
(300 mg cohort) | (gdlnabzoyu) = fturptvmdd bzfngoltft (wtkewnpuic ) View more | ||||||
Phase 2 | - | mFOLFOX6+Varlitinib | (gpdlcesdch) = sxmdaumgry xftnimabrs (zlcuwyoucg ) View more | Negative | 13 Jan 2019 | ||
mFOLFOX6+Placebo | (gpdlcesdch) = lhudczoygf xftnimabrs (zlcuwyoucg ) View more | ||||||
NCT02435927 (ESMO2018) Manual | Phase 1 | 30 | CAPOX +Varlitinib | (ucnfrxlktn) = neutropenia 5 (17%), fatigue 3(10%), transaminitis 2(7%), diarrhoea 2(7%), febrile neutropenia 2(7%), transient metabolic encephalopathy 2(7%) oknrscfmry (zduklzkzmg ) View more | Positive | 22 Oct 2018 | |
mFolfox6+Varlitinib | |||||||
Phase 2 | 50 | otrcahtfhg(whluwiimgs) = vkuooyojsi rbnfknnhpy (ixnrgdohvl ) View more | Positive | 18 Nov 2017 | |||
otrcahtfhg(whluwiimgs) = rtzmdwbpjs rbnfknnhpy (ixnrgdohvl ) View more |